Alliance for Clinical Trials in Oncology shared on X:
“Sara Tolaney of Dana-Farber leads Alliance for Clinical Trials in Oncology A012103 for early-stage breast cancer patients with complete response after chemo with pembrolizumab.
This phase III trial compares continuing pembrolizumab vs monitoring after surgery.”
Title: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Other articles featuring Sara Tolaney on OncoDaily.